These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21509910)

  • 1. Role of immunohistochemical markers in predicting progression of dysplasia to advanced neoplasia in patients with ulcerative colitis.
    van Schaik FD; Oldenburg B; Offerhaus GJ; Schipper ME; Vleggaar FP; Siersema PD; van Oijen MG; Ten Kate FJ
    Inflamm Bowel Dis; 2012 Mar; 18(3):480-8. PubMed ID: 21509910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemistry in the diagnosis of dysplasia in chronic inflammatory bowel disease colorectal polyps.
    B Brahim E; Mrabet A; Jouini R; Koubaa W; B Sidhom R; Elloumi H; Chadli A
    Arab J Gastroenterol; 2016 Sep; 17(3):121-126. PubMed ID: 27567189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R; Odze RD
    Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance.
    Navaneethan U; Jegadeesan R; Gutierrez NG; Venkatesh PG; Hammel JP; Shen B; Kiran RP
    J Crohns Colitis; 2013 Dec; 7(12):e684-91. PubMed ID: 23916526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misclassification of dysplasia in patients with inflammatory bowel disease: consequences for progression rates to advanced neoplasia.
    van Schaik FD; ten Kate FJ; Offerhaus GJ; Schipper ME; Vleggaar FP; van der Woude CJ; Stokkers PC; de Jong DJ; Hommes DW; van Bodegraven AA; Siersema PD; Oldenburg B;
    Inflamm Bowel Dis; 2011 May; 17(5):1108-16. PubMed ID: 20824815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of ATF6 as a marker of pre-cancerous atypical change in ulcerative colitis-associated colorectal cancer: a potential role in the management of dysplasia.
    Hanaoka M; Ishikawa T; Ishiguro M; Tokura M; Yamauchi S; Kikuchi A; Uetake H; Yasuno M; Kawano T
    J Gastroenterol; 2018 May; 53(5):631-641. PubMed ID: 28884228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome after surveillance of low-grade and indefinite dysplasia in patients with ulcerative colitis.
    Pekow JR; Hetzel JT; Rothe JA; Hanauer SB; Turner JR; Hart J; Noffsinger A; Huo D; Rubin DT
    Inflamm Bowel Dis; 2010 Aug; 16(8):1352-6. PubMed ID: 20027656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclin D1 and p21 in ulcerative colitis-related inflammation and epithelial neoplasia: a study of aberrant expression and underlying mechanisms.
    Wong NA; Mayer NJ; Anderson CE; McKenzie HC; Morris RG; Diebold J; Mayr D; Brock IW; Royds JA; Gilmour HM; Harrison DJ
    Hum Pathol; 2003 Jun; 34(6):580-8. PubMed ID: 12827612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemical analysis of chromogranin A and p53 expressions in ulcerative colitis-associated neoplasia: neuroendocrine differentiation as an early event in the colitis-neoplasia sequence.
    Shigaki K; Mitomi H; Fujimori T; Ichikawa K; Tomita S; Imura J; Fujii S; Itabashi M; Kameoka S; Sahara R; Takenoshita S
    Hum Pathol; 2013 Nov; 44(11):2393-9. PubMed ID: 24029705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of low grade dysplasia in patients with primary sclerosing cholangitis and ulcerative colitis.
    Venkatesh PG; Jegadeesan R; Gutierrez NG; Sanaka MR; Navaneethan U
    J Crohns Colitis; 2013 Dec; 7(12):968-73. PubMed ID: 23433613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 immunohistochemistry of ulcerative colitis-associated with dysplasia and carcinoma.
    Sato A; MacHinami R
    Pathol Int; 1999 Oct; 49(10):858-68. PubMed ID: 10571818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metallothionein: early marker in the carcinogenesis of ulcerative colitis-associated colorectal carcinoma.
    Bruewer M; Schmid KW; Krieglstein CF; Senninger N; Schuermann G
    World J Surg; 2002 Jun; 26(6):726-31. PubMed ID: 12053227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p16, cyclin D1, Ki-67, and AMACR as markers for dysplasia in Barrett esophagus.
    Shi XY; Bhagwandeen B; Leong AS
    Appl Immunohistochem Mol Morphol; 2008 Oct; 16(5):447-52. PubMed ID: 18665038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ulcerative colitis-associated colorectal cancer arises in a field of short telomeres, senescence, and inflammation.
    Risques RA; Lai LA; Himmetoglu C; Ebaee A; Li L; Feng Z; Bronner MP; Al-Lahham B; Kowdley KV; Lindor KD; Rabinovitch PS; Brentnall TA
    Cancer Res; 2011 Mar; 71(5):1669-79. PubMed ID: 21363920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sharp decline of beta estrogen receptors expression in long-lasting ulcerative-associated carcinoma.
    Principi M; Scavo MP; Piscitelli D; Villanacci V; Lovero R; Losurdo G; Girardi B; Ierardi E; Di Leo A
    Scand J Gastroenterol; 2015 Aug; 50(8):1002-10. PubMed ID: 25862314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COX-2 and Ki-67 immunohistochemical markers in the assessment of long-standing ulcerative colitis associated dysplasia.
    Frăţilă OC; Iliaş TI
    Rom J Morphol Embryol; 2013; 54(1):143-9. PubMed ID: 23529322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pattern of CD44 and matrix metalloproteinase 9 expression is a useful predictor of ulcerative colitis-associated dysplasia and neoplasia.
    AbdElazeem MA; El-Sayed M
    Ann Diagn Pathol; 2015 Dec; 19(6):369-74. PubMed ID: 26420348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.
    Eaton JE; Smyrk TC; Imam M; Pardi DS; Loftus EV; Owens VL; Talwalkar JA
    Aliment Pharmacol Ther; 2013 Oct; 38(8):977-87. PubMed ID: 24033551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis.
    Li Y; de Haar C; Chen M; Deuring J; Gerrits MM; Smits R; Xia B; Kuipers EJ; van der Woude CJ
    Gut; 2010 Feb; 59(2):227-35. PubMed ID: 19926618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.